Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IBRX
stocks logo

IBRX

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
21.95M
+1996.47%
--
--
27.85M
+356.07%
--
--
33.01M
+337.1%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for ImmunityBio, Inc. (IBRX) for FY2025, with the revenue forecasts being adjusted by -8.18% over the past three months. During the same period, the stock price has changed by 13.75%.
Revenue Estimates for FY2025
Revise Downward
down Image
-8.18%
In Past 3 Month
Stock Price
Go Up
up Image
+13.75%
In Past 3 Month
3 Analyst Rating
up Image0
Wall Street analysts forecast IBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBRX is 6.33 USD with a low forecast of 5.00 USD and a high forecast of 8.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 2.855
sliders
Low
5.00
Averages
6.33
High
8.00
up Image0
Current: 2.855
sliders
Low
5.00
Averages
6.33
High
8.00
Piper Sandler
Neutral -> Overweight
upgrade
$5
2025-05-20
Reason
Piper Sandler
Price Target
$5
2025-05-20
upgrade
Neutral -> Overweight
Reason
Piper Sandler upgraded ImmunityBio to Overweight from Neutral with a price target of $5, up from $4.25.
Piper Sandler
Neutral -> Overweight
upgrade
$5
2025-05-20
Reason
Piper Sandler
Price Target
$5
2025-05-20
upgrade
Neutral -> Overweight
Reason
Piper Sandler upgraded ImmunityBio to Overweight from Neutral with a price target of $5, up from $4.25, following a transfer of coverage. The company is developing Anktiva, t-haNK and M-ceNK cell therapies and DNA vaccines to restore the immune system's ability to kill cancer, the analyst tells investors in a research note. The firm says Anktiva is off to a strong launch in non-muscle invasive bladder cancer, with sales forecast of $83.5M in 2025. Piper sees multiple label expansion opportunities despite the refusal to file letter issued by the FDA for Anktiva in non-muscle invasive bladder cancer that is unresponsive to treatment with Bacillus Calmette-Guerin.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$30
2025-04-23
Reason
D. Boral Capital
Jason Kolbert
Price Target
$30
2025-04-23
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Andres Maldonado
Strong Buy
Reiterates
$8
2025-04-16
Reason
HC Wainwright & Co.
Andres Maldonado
Price Target
$8
2025-04-16
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$30
2025-04-15
Reason
D. Boral Capital
Jason Kolbert
Price Target
$30
2025-04-15
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$30
2025-04-09
Reason
D. Boral Capital
Jason Kolbert
Price Target
$30
2025-04-09
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Immunitybio Inc (IBRX.O) is -6.08, compared to its 5-year average forward P/E of -7.95. For a more detailed relative valuation and DCF analysis to assess Immunitybio Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.95
Current PE
-6.08
Overvalued PE
-0.63
Undervalued PE
-15.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10163.48
Current PS
0.00
Overvalued PS
28140.79
Undervalued PS
-7813.84

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

IBRX News & Events

Events Timeline

(ET)
2025-06-02
09:23:36
ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield
select
2025-05-27 (ET)
2025-05-27
08:13:30
ImmunityBio to launch Cancer BioShield in the Middle East
select
2025-05-12 (ET)
2025-05-12
06:31:38
ImmunityBio reports Q1 EPS (15c), consensus (14c)
select
Sign Up For More Events
Sign Up For More Events

News

Preview
8.0
02:00 AMNASDAQ.COM
Interesting IBRX Call Options For September 19th

  • Covered Call Strategy: Investors can buy IBRX shares at $2.76 and sell a covered call at a $3.00 strike price, potentially earning a total return of 17.75% if the stock is called away by September 19th, excluding dividends and commissions.

  • Risk and Return Analysis: The $3.00 strike represents a 9% premium to the current price, with a 25% chance of the contract expiring worthless, allowing investors to keep both their shares and the premium, which could yield an additional 9.06% return or 51.66% annualized.

Preview
9.0
07-09Newsfilter
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

  • Cancer Statistics and Research Needs: Approximately 20 million people are diagnosed with cancer annually, leading to nearly 10 million deaths worldwide. The American Cancer Society projects that by 2050, annual diagnoses could reach 35 million, highlighting the urgent need for innovative therapies and ongoing research in oncology.

  • Calidi Biotherapeutics' Innovations: Calidi Biotherapeutics is developing a next-generation platform using engineered viruses to deliver genetic medicines directly to tumors, including hard-to-treat metastatic sites. Their lead candidate, CLD-401, aims to convert "cold" tumors into "hot" targets, enhancing immune response and potentially transforming cancer treatment.

Preview
9.0
07-08NASDAQ.COM
ImmunityBio's ANKTIVA Gains UK Approval In Bladder Cancer Treatment

  • Regulatory Approval: ImmunityBio Inc. received marketing authorization from the UK MHRA for ANKTIVA, a treatment for certain bladder cancer patients, marking its first approval outside the U.S.

  • Expansion Plans: The company has submitted applications to the European Medicines Agency to broaden the availability of ANKTIVA across the EU and additional countries.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Immunitybio Inc (IBRX) stock price today?

The current price of IBRX is 2.855 USD — it has increased 0.88 % in the last trading day.

arrow icon

What is Immunitybio Inc (IBRX)'s business?

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.

arrow icon

What is the price predicton of IBRX Stock?

Wall Street analysts forecast IBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBRX is 6.33 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Immunitybio Inc (IBRX)'s revenue for the last quarter?

Immunitybio Inc revenue for the last quarter amounts to 16.52M USD, increased 41192.50 % YoY.

arrow icon

What is Immunitybio Inc (IBRX)'s earnings per share (EPS) for the last quarter?

Immunitybio Inc. EPS for the last quarter amounts to -0.15 USD, decreased -25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Immunitybio Inc (IBRX)'s fundamentals?

The market is revising Downward the revenue expectations for ImmunityBio, Inc. (IBRX) for FY2025, with the revenue forecasts being adjusted by -8.18% over the past three months. During the same period, the stock price has changed by 13.75%.
arrow icon

How many employees does Immunitybio Inc (IBRX). have?

Immunitybio Inc (IBRX) has 680 emplpoyees as of July 18 2025.

arrow icon

What is Immunitybio Inc (IBRX) market cap?

Today IBRX has the market capitalization of 2.50B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free